Vince Burgess

The strategic plan outlines the Cancer Prevention and Research Institute of Texas's roadmap to expedite discoveries and innovations in cancer prevention, detection, treatment, and cures across Texas. It focuses on three statutory goals: attracting and expanding research capabilities in higher education, fostering private sector growth and job creation, and accelerating breakthroughs in cancer prevention and cures. Key initiatives include enhancing childhood cancer research, expanding prevention services, increasing clinical trial access, and strengthening Texas's position as a biotechnology hub. The plan also prioritizes accountability, efficiency, transparent operations, and excellent customer service, supported by modern information technology goals aimed at providing an exceptional government experience, responsible data management, a skilled workforce, and modernized services through emerging technologies.

The document provides an impact report detailing the measurable results of The Cancer Prevention & Research Institute of Texas (CPRIT)'s $6 billion strategic initiative to fight cancer in Texas. It highlights the institute's three-fold mission: investing in research prowess, expanding life science infrastructure, and expediting innovation breakthroughs in prevention and cures. Key outcomes include the recruitment of 351 scholars and 25 companies, the establishment of three NCI comprehensive cancer centers, generation of $12.45 billion in follow-on funding, and the delivery of 11.8 million prevention services across all 254 Texas counties, leading to the detection of 58,507 cancers and precursors.

The committee held a presentation by Omni Nano regarding a grantee project focused on developing a drug delivery system for solid tumors, specifically pancreatic cancer. The discussion covered the mechanism of the nano-polymeric drug, its efficacy in pre-clinical studies in penetrating tumor stroma, and its potential to improve therapeutic outcomes by enhancing tumor-specific delivery while reducing systemic exposure. Additionally, the committee received updates on the progress of seed grant goals, including dose optimization, ongoing toxicology studies, and chemical synthesis processes for the drug product.

The committee meeting featured a presentation from a grantee, the CEO of Omni Nano, regarding the development of a therapeutic approach for treating solid tumors, specifically focusing on pancreatic cancer. Discussion points included the mechanism of their nano-medicine drug delivery system, preclinical study results demonstrating tumor concentration and survival benefits, and the company's progress on its seed grant goals, including dose optimization, toxicology studies, and the drug synthesis process.

The committee meeting covered a wide range of administrative, compliance, and programmatic topics. These included CEO, compliance, scientific, and product development officer reports, alongside recommendations for academic research and product development grant awards. Discussions also encompassed the appointment of members to various advisory and scientific research committees, proposed amendments to administrative rules, financial status updates, legislative appropriation requests, and bond issuance resolutions. Additionally, the committee addressed internal audit reports, compliance training, and preparations for upcoming conferences.